How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

The pharmacokinetics (PK) of RO7049389, a new hepatitis B virus (HBV) core protein allosteric modulator of class I, and of its active metabolite M5 were studied in fasted and fed conditions after single and multiple once‐a‐day and twice‐a‐day doses in healthy subjects and patients with HBV. The nonl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosson, Valérie, Feng, Sheng, Jaminion, Felix, Lemenuel‐Diot, Annabelle, Parrott, Neil, Paehler, Axel, Bo, Qingyan, Jin, Yuyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048879/
https://www.ncbi.nlm.nih.gov/pubmed/33523474
http://dx.doi.org/10.1002/cpt.2184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048879/
https://www.ncbi.nlm.nih.gov/pubmed/33523474
http://dx.doi.org/10.1002/cpt.2184

Ejemplares similares